Abstract
Poor prognosis of intra-tumoural TRBV6-6 variants in EGFR-mutant NSCLC: Results from the ADJUVANT-CTONG1104 trial.
Full Text
Sign-in/Register to access full text options
Published version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have